DE
REGN icon

DV Equities’s Regeneron Pharmaceuticals REGN Stock Holding History

DV Equities’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$110K Buy
+142
New +$96.4K 0.02% 202

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

DV Equities's REGN Position: Q4 2025 in Review

DV Equities opened a new position in Regeneron Pharmaceuticals (REGN) in Q4 2025: 142 shares worth $110K. The stake represents 0.02% of the portfolio and ranks #202 among its holdings.

1,388 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • DV Equities held 142 shares of Regeneron Pharmaceuticals worth $110K as of Q4 2025.
  • Regeneron Pharmaceuticals was a new DV Equities position in Q4 2025.
  • Regeneron Pharmaceuticals made up 0.02% of DV Equities's portfolio in Q4 2025, its #202 holding.
  • 1,388 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on DV Equities's 13F filing for Q4 2025, filed 17 Feb 2026.